|
| Status |
Public on Feb 22, 2018 |
| Title |
AG221 and Ruxolitinib Treatment Effects on LSKs in IDH2-R140Q JAK2-V617F Transplant Recipients |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Transplant recipients of IDH2-R140Q JAK2-V617F expressing bone marrow were treated with AG221 and ruxolitinib monotherapy, combined therapy, or vehicle. LSKs were sorted from terminal samples and sequenced with three WT controls.
|
| |
|
| Overall design |
15 samples
|
| |
|
| Contributor(s) |
McKenney AS, Spitzer B, Levine RL |
| Citation(s) |
29355841 |
| |
| Submission date |
Mar 07, 2017 |
| Last update date |
May 15, 2019 |
| Contact name |
Barbara Spitzer |
| E-mail(s) |
spitzerb@mskcc.org
|
| Organization name |
Memorial Sloan Kettering Cancer Center
|
| Lab |
Levine Lab
|
| Street address |
411 E 67th St
|
| City |
New York |
| State/province |
NY |
| ZIP/Postal code |
10065 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL17021 |
Illumina HiSeq 2500 (Mus musculus) |
|
| Samples (15)
|
|
| Relations |
| BioProject |
PRJNA378381 |
| SRA |
SRP101495 |
Less...
More...